Considering the published report demonstrating the anti-tumor effects of apCAFs in NSCLC through direct activation of CD4+ effector T cells (17), we next examined the relationship between apCAFs and CD4+ effector T cells across various types of solid tumor. The gene discussed is CD4; the disease is non-small cell lung carcinoma.